Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | UKALL2011: ABL-class fusions & TKIs

Anthony Moorman • 22 Jun 2020
EHA 2020
Acute Lymphoblastic Leukemia Leukemia Imatinib
ALLTogether1 UKALL2011

Anthony Moorman, PhD, Newcastle University, Newcastle, UK discusses preliminary data from UKALL2011, focussing on ABL-class fusion acute lymphoblastic leukemia (ALL) and the use of tyrosine kinase inhibitors (TKIs). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Anthony Moorman

5:23
Redefining low risk high hyperdiploidy in pediatric ALL
Anthony Moorman • 8 Jun 2021
4:31
T-ALL diagnosis: cytogenetics, genomics and risk assessment
Anthony Moorman • 8 Jun 2021
2:44
Impact of genomics in the future of ALL treatment
Anthony Moorman • 8 Jun 2021
3:02
Enhanced risk stratification in pediatric ALL
Anthony Moorman • 10 Nov 2020

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals